共 88 条
- [1] Fanouriakis A(2024)EULAR recommendations for the management of systemic lupus erythematosus: 2023 update Ann Rheum Dis 83 15-29
- [2] Kostopoulou M(2008)EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for International Clinical Studies including Therapeutics Ann Rheum Dis 67 195-205
- [3] Andersen J(2019)2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Ann Rheum Dis 78 736-745
- [4] Bertsias G(2016)Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) Ann Rheum Dis 75 1615-1621
- [5] Ioannidis JP(2014)Treat-to-target in systemic lupus erythematosus: recommendations from an international task force Ann. Rheum. Dis. 73 958-967
- [6] Boletis J(2021)Systemic lupus erythematosus Internist 62 385-396
- [7] Fanouriakis A(2016)Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision) Ophthalmology 123 1386-1394
- [8] Kostopoulou M(2023)Association between severe Nonadherence to Hydroxychloroquine and systemic Lupus Erythematosus Flares, damage, and mortality in 660 patients from the SLICC Inception Cohort Arthritis Rheumatol 75 2195-2206
- [9] Alunno A(2024)Reference range of Hydroxychloroquine blood levels that can reduce odds of active lupus and prevent flares Arthritis & Rheumatism 76 241-250
- [10] Franklyn K(2022)Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort Ann Rheum Dis 81 370-378